论文部分内容阅读
目的观察经皮穿刺药盒植入动脉内序贯化疗加大剂量白介素-2生物免疫治疗中晚期肝癌的疗效。方法采取经皮右股动脉穿刺置管右股部皮下埋置药盒序贯动脉内化疗加栓塞术治疗35例中晚期肝癌患者,并经药盒注入或静脉滴注大剂量白介素-2。治疗1～6个月CT复查,依据瘤体缩小情况、碘油沉积、肿瘤血管变化、AFP水平变化情况判断近期疗效;观察治疗6个月及1、2、3年的生存率,判断远期疗效。结果 35例患者的近期疗效:有效24例,总有效率68.6%;稳定9例(25.7%);进展2例(5.7%)。远期疗效:6个月、1、2、3年生存率分别为85.7%、65.7%、42.9%和14.3%。结论药盒植入化疗加免疫疗法对中晚期肝癌有一定疗效,其操作简单,可降低医患放射剂量,减轻患者负担,值得推广。
Objective To observe the effect of percutaneous puncture kit implantation of intra-arterial sequential chemotherapy plus large-dose interleukin-2 bioimmunotherapy in the treatment of advanced hepatocellular carcinoma. Methods Percutaneous right femoral artery catheterization of the right subcutaneous subcutaneous embedded kit sequential intra-arterial chemotherapy and embolization in the treatment of 35 cases of advanced liver cancer patients, and injected by injection or intravenous injection of high-dose interleukin-2. Treatment of 1 to 6 months CT review, according to tumor reduction, lipiodol deposition, tumor vascular changes, AFP level changes to determine the short-term efficacy; observed 6 months and 1, 2, 3 years survival rate, to determine the long-term Efficacy. Results The short-term curative effect of 35 patients: effective in 24 cases, the total effective rate was 68.6%; stable in 9 cases (25.7%); progression in 2 cases (5.7%). Long-term efficacy: 6 months, 1, 2, 3-year survival rates were 85.7%, 65.7%, 42.9% and 14.3%. Conclusion The combination of chemotherapy and immunotherapy with drug-kit has some curative effect on advanced hepatocellular carcinoma. The operation is simple, which can reduce the radiation dose and reduce the burden on patients, which is worth to be popularized.